Status: Not yet recruiting
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.
Participants needed: 50
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: Collegium Medicum w BydgoszczyUpdated: Oct 2, 2025Locations: 1
Eligibility criteria
Between 18 and 80 years of age [+4]
History of hypersensitivity to rifaximin or other rifamycin-derived agent [+11]